Ibrutinib Therapy - Mantle Cell Lymphoma. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Ibrutinib Therapy - Mantle Cell Lymphoma, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6953/297_Ibrutinib_MCL.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). 2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations Biomarkers Cancer types Therapies
HSE (1) t(11;14) Mantle Cell Lymphoma Ibrutinib
HSE (1) CCND1 Mantle Cell Lymphoma Ibrutinib